Bluebird bio’s treatment for a
rare blood disorder received backing from advisers to the U.S.
Food and Drug Administration on Friday, in a vote of confidence
in gene therapies and bolstering the company beset by regulatory
(Reporting by Mrinalika Roy in Bengaluru; Editing by Maju